SLC5A2 and type 2 diabetes mellitus: In a clinical experiment, combination therapy with the SGLT2 inhibitor dapagliflozin attenuated hyperglycemia in patients with type 2 diabetes that was inadequately controlled using pioglitazone monotherapy (Rosenstock, Vico, Wei, Salsali, & List, 2012).